文献速递急性肾损伤遗传性与小管间质肾病

接种mRNA-1273新冠疫苗加强针后发生非典型溶血性尿毒症综合征:一例病例报告

Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report.
PubMed 文献 · Am J Kidney Dis · 2022-09-19

一例38岁既往健康女性在接种mRNA-1273新冠疫苗加强针后1天出现不适,因持续头痛、恶心和全身乏力就诊,发现高血压和急性肾损伤,诊断为血栓性微血管病(TMA),经降压、血液透析、血浆置换和呼吸支持治疗,肾活检证实急性TMA,接受依库珠单抗治疗后肾功能改善,基因分析发现致病性C3变异。作者认为疫苗可能是该患者发生非典型溶血性尿毒症综合征(aHUS)的触发因素。

要点

  • 接种mRNA-1273新冠疫苗加强针后1天出现aHUS相关表现,时间上提示疫苗可能为触发因素。
  • 肾活检证实急性TMA,基因分析发现致病性C3变异。
  • 接受依库珠单抗治疗后肾功能改善。

核心结论

  • 作者认为,鉴于时间框架,疫苗可能是该患者发生aHUS的触发因素。

研究设计与样本

  • 病例报告:一例38岁既往健康女性在接种mRNA-1273新冠疫苗加强针后发生aHUS。

主要发现

  • 接种mRNA-1273疫苗加强针后1天,患者出现不适。
  • 因持续头痛、恶心和全身乏力就诊,发现高血压和急性肾损伤,诊断为TMA。
  • 肾活检证实急性TMA;基因分析发现致病性C3变异。
  • 治疗包括血压控制、血液透析、血浆置换和呼吸支持;转诊接受依库珠单抗治疗后肾功能改善。

关键数值与推荐

  • 基因分析发现致病性C3变异。
  • 肾活检证实急性TMA。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atypical hemolytic uremic syndrome (aHUS) is a subtype of thrombotic microangiopathy (TMA) characterized by a dysregulation of the alternative complement pathway. Here, we report a previously healthy 38-year-old woman in whom aHUS developed after a COVID-19 vaccine booster. One day after receipt of a booster dose of mRNA-1273 vaccine, she felt ill. Because of persistent headache, nausea, and general malaise, she went to her general practitioner, who referred her to the hospital after detecting hypertension and acute kidney injury. A diagnosis of TMA was made. Her treatment consisted of blood pressure control, hemodialysis, plasma exchange, and respiratory support. Kidney biopsy confirmed the diagnosis of acute TMA. The patient was referred for treatment with eculizumab, and kidney function improved after initiation of this therapy. Genetic analysis revealed a pathogenic C3 variant. SARS-CoV-2 infection as a trigger for complement activation and development of aHUS has been described previously. In addition, there is one reported case of aHUS occurring after receipt of the adenovirus-based COVID-19 vaccine ChAdOx1 nCoV-19, but, to our knowledge, this is the first case of aHUS occurring after a booster dose of an mRNA COVID-19 vaccine in a patient with an underlying pathogenic variant in complement C3. Given the time frame, we hypothesize that the vaccine probably was the trigger for development of aHUS in this patient.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Claes KJ, Geerts I, Lemahieu W, et al. Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report. Am J Kidney Dis. 2022. PMID: 36342000. doi:10.1053/j.ajkd.2022.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。